Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
Zepbound and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
FDA approves Lilly's EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non?communicable Disease and Chronic Conditions
Lilly's oral GLP-1 Foundayo delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Lilly's Foundayo , the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association Annual Meeting
Lilly's Retevmo demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
